Acadia postpones NDA for 'breakthrough' Parkinson's drug; Alchemia CEO exits;

@FierceBiotech: Amgen takes another stride in frenzied race toward the PCSK9 finish line. More | Follow @FierceBiotech

@JohnCFierce: Triple shot IL-13/IL-4 -- Promising asthma trial prompts Regeneron, Sanofi to push dupilumab into PhIII. More | Follow @JohnCFierce

@DamianFierce: I had missed this excellent tick-tock of the last days of one Christopher A. Viehbacher. More | Follow @DamianFierce

> Acadia disappointed investors with the news that it will delay its planned NDA for the Parkinson's drug pimavanserin (Nuplazid). The biotech--which recently won 'breakthrough' status for the treatment--now plans to file in the first quarter of 2015. Its shares were down 3% this morning. Release

> Australia's Alchemia says CEO Thomas Liquard has left the company and will be temporarily replaced by non-executive chairman Tracie Ramsdale. Release

Medical Device News

@FierceMedDev: China FDA's new medical device importation regulations shorten review period. More | Follow @FierceMedDev

@VarunSaxena2: Device that performs hundreds of tests with a single drop of blood wins Nokia Sensing Xchallenge. More | Follow @VarunSaxena2

> Thync rolling out wearable, noninvasive device to elevate mood with fresh infusion of cash in tow. More

> Medtronic makes concessions to European regulator in bid to close Covidien deal. News

> OrthAlign secures $15M to launch new navigation system for orthopedic surgery. Article

Pharma News

@FiercePharma: Top-read special report: The top 10 pharma companies by 2013 revenue. More | Follow @FiercePharma

@EricPFierce: Fresenius Russian partnership tanks even as Russian tanks spotted rolling into Ukraine. Story | Follow @EricPFierce

@CarlyHFierce: Dendreon bankruptcy weighs on cancer vaccine field. More | Follow @CarlyHFierce

> Take as directed? U.K. health service teams with academics, pharmacy on drug adherence. News

> Merck's head-to-head Vytorin trial might be surprisingly flattering. More

Biotech Research News

> Small human study will test a new approach to fighting diabetes. More

> Research team points to Sestrin 3 as a potential new target in diabetes. Article

> Harvard investigators prep an animal study of CRISPR Cas tech for HIV. Story

> Swiss team at ETH spotlights potential of a new antibiotic found in nature. More

> Genentech R&D team fixes a flawed approach to Alzheimer's. Report

Pharma Manufacturing News

> Cadila API plant slapped for faulty follow-up on stinking APIs. Article

> Dr. Reddy's, Endo benefit from Ranbaxy manufacturing shortfalls. Item

> Plant power outage zaps the juice from AMRI's earnings. More

> Dendreon, done in by expensive, complex manufacturing, files for bankruptcy. Story

> Fresenius expansion plans in Russia sidelined by political turmoil. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.